Incyclinide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Bender the Bot (talk | contribs) at 07:06, 1 July 2017 (→‎References: HTTP→HTTPS for Reuters, per BRFA 8 using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Incyclinide
Clinical data
Trade namesMetastat (proposed)
ATC code
  • none
Legal status
Legal status
  • Abandoned?
Identifiers
  • (4aS,5aR,12aS)-3,10,12,12a-Tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydronaphthacen-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H17NO7
Molar mass371.345 g·mol−1
3D model (JSmol)
  • c1cc2c(c(c1)O)C(=O)C3=C([C@]4([C@@H](C[C@@H]3C2)CC(=C(C4=O)C(=O)N)O)O)O
  • InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21-22,24,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1
  • Key:ZXFCRFYULUUSDW-OWXODZSWSA-N

Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions. The drug has no antibiotic properties.[2][3][4]

Mechanism of action

Like other tetracyclines, incyclinide inhibits matrix metalloproteinases.[2]

References

  1. ^ Reuters: CollaGenex says incyclinide ineffective for rosacea
  2. ^ a b Viera, MH, Perez, OA, Berman, B. "Incyclinide". Drugs of the Future. 32 (3): 209–214.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ H. Spreitzer (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
  4. ^ ClinicalTrials.gov: Incyclinide